Mankind Pharma reports 55% YoY growth in PAT for Q3 FY24
Revenue from Operations stood at Rs. 2,607 crore, 25% YoY growth. Domestic revenue at Rs. 2,400 crore, 20% YoY growth and export revenue at Rs. 207 crore, 118% YoY growth
Revenue from Operations stood at Rs. 2,607 crore, 25% YoY growth. Domestic revenue at Rs. 2,400 crore, 20% YoY growth and export revenue at Rs. 207 crore, 118% YoY growth
The esteemed duo perfectly embody the brand's core values of family, love, and the special bond we share with our pets
Mankind Pharma has reported total income of Rs. 2768.07 crores during the period ended September 30, 2023
Prateek has more than 23 years of rich experience in Human Resource
Mankind Pharma commences the commercial operations newly set-up plant in Udaipur
Mankind Pharma's initiative aims to ensure universal access to medicines of international calibre
Cipla has a robust governance model focused on sustainability
Witnessing sizable consolidation (M& A) activity with Domestic Formulations and Hospitals being two areas wherein maximum M&A has occurred.
Tobacco smoke increases infant morbidity and is fatal to a baby because it damages the baby’s organs
Candle Partners, an investment banking & advisory service for M&A among others, has closed many deals in the healthcare space. Ankit Poddar, Director, Candle Partners spoke to Thomas C Thottathil, Editor, Indianpharmapost.com about the prospects for the industry.
Subscribe To Our Newsletter & Stay Updated